+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Randomised double blind controlled study of recurrence of gastric ulcer after treatment for eradication of Helicobacter pylori infection

Randomised double blind controlled study of recurrence of gastric ulcer after treatment for eradication of Helicobacter pylori infection

Bmj 314(7080): 565-568

Objective: To determine whether eradication of Helicobacter pylori infection reduces recurrence of benign gastric ulceration. Design: Randomised, double blind, controlled study. Patients were randomised in a 1:2 ratio to either omeprazole 40 mg once daily for eight weeks or the same treatment plus amoxycillin 750 mg twice daily for weeks 7 and 8. A 12 month untreated follow up ensued. Setting: Teaching and district general hospitals between 1991 and 1994. Subjects: 107 patients with benign gastric ulcer associated with H. pylori. Main outcome measures: Endoscopically confirmed relapse with gastric ulcer (analysed with life table methods), H. pylori eradication, and healing of gastric ulcers (Mantel-Haenszel test). Results: 172 patients were enrolled. Malignancy was diagnosed in 19; 24 were not infected with H. pylori; four withdrew because of adverse events; and 18 failed to attend for start of treatment, leaving 107 patients eligible for analysis (35 omeprazole alone; 72 omeprazole plus amoxycillin). In the omeprazole/amoxycillin group 93% (67/72; 95% confidence interval 84% to 98%) of gastric ulcers healed and 83% (29/35; 66% to 94%) in the omeprazole group (P=0.103). Eradication of H. pylori was 58% (42/72; 46% to 70%) and 6% (2/35; 1% to 19%) (P lt 0.001) and relapse after treatment was 22% (16/72) and 49% (17/35) (life table analysis, P lt 0.001), in the two groups, respectively. The recurrence rates were 7% (3/44) after successful H. pylori eradication and 48% (30/63) in those who continued to be infected (P lt 0.001). Conclusions: Eradication of H. pylori reduces relapse with gastric ulcer over one year. Eradication rates achieved with this regimen, however, are too low for it to be recommended for routine use.

(PDF emailed within 1 workday: $29.90)

Accession: 009295453

Download citation: RISBibTeXText

PMID: 9055715

Related references

Helicobacter pylori eradication in the healing and recurrence of benign gastric ulcer: a two-year, double-blind, placebo controlled study. Italian Journal of Gastroenterology and Hepatology 29(3): 220-227, 1997

The recurrence of duodenal ulcer after treatment for Helicobacter pylori. A randomized, double-blind, placebo-controlled study. G.E.N 46(4): 302-306, 1992

Does treatment of Helicobacter pylori with antibiotics alone heal duodenal ulcer ? A randomised double-blind placebo-controlled study. Gastroenterology 110(4 SUPPL ): A169, 1996

The effects of Helicobacter pylori eradication on abdominal and dyspeptic complaints in previously vagotomized peptic ulcer patients A prospective, randomised, double blind, placebo controlled study without pretreatment diagnostic gastroscopy. Gut 41(SUPPL 1): A127, 1997

Duodenal ulcer recurrence after Helicobacter pylori eradication or maintenance therapy A randomized, double blind study. Gastroenterology 112(4 SUPPL ): A193, 1997

Does eradication of Helicobacter pylori influence the recurrence of symptoms in patients with symptomatic gastro-oesophageal reflux disease? - A randomised double blind study. Gut 44(SUPPL 1): A112, April, 1999

Helicobacter pylori eradication for non-ulcer dyspepsia A prospective, double-blind, randomized, placebo controlled study. Gastroenterology 110(4 SUPPL ): A91, 1996

Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Annals of Internal Medicine 116(9): 705-708, 1992

Clinical trial: irsogladine maleate, a mucosal protective drug, accelerates gastric ulcer healing after treatment for eradication of Helicobacter pylori infection--the results of a multicentre, double-blind, randomized clinical trial (IMPACT study). Alimentary Pharmacology & Therapeutics 31(8): 824-833, 2010

Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal refux disease: A double blind, placebo controlled, randomised trial. Gut 53(2): 174-179, February, 2004

Helicobacter pylori eradication in non-ulcer dyspepsia A randomized, double-blind, placebo-controlled study with a 12-month follow-up. Gastroenterology 118(4 Suppl 2 Part 1): AGA A468, April, 2000

Duodenal ulcer recurrence after treatment of Helicobacter pylori Double blind, randomized placebo controlled trial Two years follow up. Gastroenterology 104(4 SUPPL ): A171, 1993

Three days 1000mg vs 500mg daily Azithromycin with Tinidazole and Omeprazole for Helicobacter pylori eradication A double blind randomised, placebo controlled multicenter study. Gut 49(Supplement 11): A84, September, 2001

Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. Bmj 318(7187): 833-837, 1999